CSIMarket
 
Century Therapeutics inc   (IPSC)
Other Ticker:  
 
 
Price: $5.0000 $0.49 10.865%
Day's High: $5.045 Week Perf: -3.1 %
Day's Low: $ 4.81 30 Day Perf: 11.36 %
Volume (M): 262 52 Wk High: $ 5.51
Volume (M$): $ 1,312 52 Wk Avg: $2.94
Open: $4.81 52 Wk Low: $1.28



 Market Capitalization (Millions $) 301
 Shares Outstanding (Millions) 60
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -137
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 14

Century Therapeutics Inc
Century Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing genetically engineered immune cells for cancer therapy. The company utilizes induced pluripotent stem cells (iPSCs) to create immune cells, such as T cells and natural killer (NK) cells, that have enhanced anti-tumor properties. By reprogramming these cells, Century aims to improve their efficacy and safety for use in cancer treatment. Their ultimate goal is to develop off-the-shelf cell therapies that can be readily available to treat a wide range of tumors. Century Therapeutics is based in Philadelphia, Pennsylvania, and was founded in 2018.


   Company Address: 25 N 38th Street, 11th Floor Philadelphia 19104 PA
   Company Phone Number: 817-5790   Stock Exchange / Ticker: NASDAQ IPSC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Century Therapeutics Inc

IPSC's Top-Line Takes a Dive as Fiscal Period Closes in December 2023

Century Therapeutics Inc (NASDAQ: CNTY) has seen a significant drop in its stock price in March 2024, with a decrease of 19.95% so far. However, over the past 12 months, the stock has still managed to increase by 3.76%. Currently, the stock is trading on the NASDAQ at a price that is 62.3% above its 52-week average.
These fluctuations in the stock price can be attributed to the company's financial performance. According to their fiscal period closing on December 31, 2023, Century Therapeutics Inc reported an increase in loss per share. The loss per share increased to $-0.66 compared to $-0.30 in the previous year, and the loss grew from $-0.55 in the preceding reporting season. The company's revenue also experienced a decline of 48.56% from $0.52 million to $0.27 million in the comparable reporting season a year prior. However, the revenue showed a sequential surge of 81.081% from $0.15 million.

Clinical Study

Century Therapeutics Showcases CAR iNK Therapy Potential Amid Revenue Decline

Published Sat, Dec 9 2023 5:00 PM UTC



Philadelphia-based biotechnology company Century Therapeutics Inc. recently presented initial data from the CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The results highlight the potential for a multi-dosing strategy for CAR iNK therapy enabled by allo-evasion edits. In addition, the therapy was found to be generally well tolerated in a high-risk...

Century Therapeutics Inc

Century Therapeutics Inc Shatters Expectations with Record Shortfall in IPSC Earnings Season



The stock market has recently witnessed some distressing news concerning Century Therapeutics Inc's financial performance in the third quarter of 2023. The company reported alarming figures, including a staggering decline in revenue and an increased net loss per share compared to the previous year. Let's delve deeper into the interesting facts revealed by IPSC's financial report and understand their implications for investors.
Revenue Plunges, but Sequential Recovery Noticed:
In the third quarter of 2023, Century Therapeutics Inc's revenue plummeted by a shocking -93.345% to a mere $0.15 million. This drastic decline is undoubtedly a cause for concern for the company and its investors. However, an interesting observation is that the revenue witnessed a sequential recovery, surging by 49.495% from the preceding quarter's $0.10 million. Although this recovery is relatively small in terms of absolute numbers, it indicates some potential possibilities for the company's future growth.

Century Therapeutics Inc

Century Therapeutics Inc Faces Deepening Losses in Second Quarter of 2023, Casting Doubt on Future Prospects



Biotechnology & Pharmaceuticals company, Century Therapeutics Inc, has recently reported extremely disappointing financial results for the second quarter ending June 30, 2023. The company's revenue plummeted by a staggering -92.908% to only $0.10 million, while the net deficit per share expanded to $-0.56 from the same quarter a year ago. Furthermore, compared to the previous quarter, revenue experienced a drastic sequential tumble of -94.244% from $1.72 million. These alarming results have caused concern in the market and have contributed to a decline in the company's share price.
Financial Analysis:
1. Revenue Decline: Century Therapeutics Inc's revenue declined by -92.908% to $0.10 million compared to the same quarter last year. This significant reduction in revenue indicates a notable setback in the company's overall financial performance.
2. Widening Net Deficit: The net deficit per share for Century Therapeutics Inc has widened from $-0.53 per share in the previous quarter to $-0.56 per share. This indicates a worsening financial position, further raising concerns about the company's ability to generate profits.

Century Therapeutics Inc

Century Therapeutics Inc Sees Strong Revenue Growth of 62.571% in First Quarter 2023, but Caution Advised for Investors

Investors should exercise caution when considering investing in Century Therapeutics Inc, given its recorded net loss of $-125 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on equity (ROE) of -39.33%. This performance places it below 69 other companies within the Biotechnology & Pharmaceuticals industry, indicating that there may be other investment opportunities with higher ROEs.
However, there are some positive signs, as the company's overall ranking for ROE has advanced in the current quarter, moving up to 2287 from 3345 in the previous quarter. Additionally, the company's revenue grew strongly, increasing by 62.571% to $1.72 million compared to the same period a year ago. Furthermore, the company reported a smaller net shortfall of $-31.264 million instead of a deficit of $-37.513 million in the previous comparable reporting season.






 

Century Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Century Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Century Therapeutics inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com